Soleno Therapeutics
SLNO
SLNO was delisted on the 15th of May, 2026.
11 hedge funds and large institutions have $15.9M invested in Soleno Therapeutics in 2017 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 8 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
87% more capital invested
Capital invested by funds: $8.5M → $15.9M (+$7.43M)
56.14% more ownership
Funds ownership: 33.4% → 89.54% (+56%)
21% less funds holding
Funds holding: 14 → 11 (-3)
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
+$4.59M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
+$2.1M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.76M |
| 4 |
6CM
683 Capital Management
New York
|
+$1.56M |
| 5 |
BC
Birchview Capital
Burlington,
Vermont
|
+$1.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$311K |
| 2 |
PAI
Palo Alto Investors
Palo Alto,
California
|
-$220K |
| 3 |
VF
Virtu Financial
New York
|
-$28K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$14K |
| 5 |
Renaissance Technologies
New York
|
-$14K |
SLNO Hedge Fund Activity: Q4 2017 in Review
11 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q4 2017, worth a combined $15.9M — up 87% from $8.5M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of SLNO and 5 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 3 added.
The largest buyer was Oracle Investment Management, opening a new position worth an estimated $4.59M. The largest seller was Deutsche Bank, exiting entirely with an estimated $311K sold.
- 11 institutional investors held Soleno Therapeutics (SLNO) as of Q4 2017, down from 14 in Q3 2017.
- Funds reported $15.9M of Soleno Therapeutics stock for Q4 2017, up 87% quarter-over-quarter.
- 5 funds opened new Soleno Therapeutics positions in Q4 2017 and 8 closed out, a net change of -3 holders.
- The largest Soleno Therapeutics buyer in Q4 2017 was Oracle Investment Management, an estimated $4.59M added.
- The largest Soleno Therapeutics seller in Q4 2017 was Deutsche Bank, an estimated $311K sold.
Based on aggregated 13F filings for Q4 2017.